Skip to main content
. 2018 Jun 21;9:664. doi: 10.3389/fphar.2018.00664

FIGURE 4.

FIGURE 4

Trimebutine promotes cell apotosis in glioma cells. (A–C) Three cell lines were treated with 0, 10, 50, 100, and 200 μM of trimebutine for 48 h, and then stained with Annexin V-EGFP/PI. The percentage of apoptotic cells was determined using flow cytometry. The data are presented as the means ± SEM for 3 independent experiments. ∗P < 0.05 and ∗∗P < 0.01 vs. vehicle control group. (D) Western blot analysis showed the protein expression of Bcl-2 and Bax in three glioma/glioblastoma cell lines treated with 0, 10, 50, 100, and 200 μM of trimebutine for 48 and 72 h. DMSO was used as the vehicle control. (E) Western blot analysis showed the protein levels of both full length and cleaved Caspase-3 in three glioma/glioblastoma cell lines treated with 0, 10, 50, 100, and 200 μM of trimebutine for 48 and 72 h. DMSO was used as the vehicle control. (F) Photographs showing cells stained with the active Caspase-3 antibody (red) under a fluorescence microscope. Nuclei were counterstained with DAPI (blue). Scale bar, 200 μm.